In case PRCA is diagnosed, therapy with Aranesp must be discontinued and patients should not be switched to another recombinant erythropoietic protein (see section 4.4).
PRCA diagnoosimisel tuleb ravi Aranesp’ iga katkestada ning patsiente ei tohi üle viia teisele rekombinantsele erütropoetiinproteiinile (vt lõik 4. 4).